MFN2 and metabolic dysfunction-associated steatohepatitis: Our data demonstrated that Mfn‐2 overexpression could markedly decrease the lipotoxicity of NEFAs on mitochondrial function and insulin sensitivity, indicating that Mfn‐2 is a potential therapeutic target for insulin resistance in NASH.